Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Status:
Completed
Trial end date:
2018-12-20
Target enrollment:
Participant gender:
Summary
The need to understand LABC is especially compelling in populations and countries with
limited resources, where breast cancer incidence is relatively low, but mortality is
comparably high. In these settings access to appropriate cancer care is characteristically
limited or often plainly nonexistent. In contrast to economically developed nations, where on
average fewer than 20% of women present with breast cancer at advanced stages, LABC and
metastatic disease are the most common stages at presentation in 50% or more women in Latin
America, Asia and Africa.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health